27Gy/6次姑息IMRT联合早期姑息治疗的单臂II期研究
GOAL27-6单臂II期研究评估不适合根治的头颈鳞癌患者接受27Gy/6次姑息IMRT并早期整合姑息治疗后的生活质量与毒性。生活质量改善/维持者中位生存10个月,恶化者4.4个月(p<0.001)。
要点
- 27Gy/6次姑息IMRT联合早期姑息治疗可整体改善患者及照护者生活质量。
- 生活质量改善/维持者中位生存10个月,恶化者4.4个月(p<0.001)。
核心结论
- 27Gy/6次IMRT联合早期姑息治疗可整体改善患者及照护者生活质量。
- 治疗反应与生活质量相关性弱(ρ=0.23,p=0.13),患者/照护者的生活质量目标可能受益于早期探索。
研究设计与样本
- 单臂II期研究,纳入不适合根治治疗且接受 upfront 姑息治疗转诊的头颈鳞癌患者。
- 主要终点为FACT-HN评估的生活质量和CTCAE v5.0评估的治疗毒性;次要终点包括CarGoQoL评估的照护者生活质量、治疗反应和生存。
- FACT-HN生活质量改善预设为总分≥5%、恶化预设为≥-10%;CarGoQoL全局指数改善预设为≥3.65分、恶化预设为≥-4.13分。
主要发现
- 32例可评估患者FACT-HN平均分在27Gy/6次后第12周和第18周分别提高5%和8%(标准差SD=26)。
- 30例可评估照护者中20例(67%)生活质量改善,8例(27%)维持不变,2例(7%)恶化;CarGoQoL全局指数第12周和第18周分别提高6.65分(SD=22)和8.40分(SD=16)。
- 18例(56%)患者达完全/部分缓解,7例(22%)疾病稳定,7例(22%)进展。
- 生活质量改善/维持患者中位生存10个月,生活质量恶化患者4.4个月(p<0.001)。
关键数值与推荐
- FACT-HN生活质量改善定义为总分较基线提高≥5%,恶化定义为≥-10%。
- CarGoQoL全局指数改善定义为≥3.65分,恶化定义为≥-4.13分。
- 治疗毒性按CTCAE v5.0评估,研究中无≥3级治疗毒性。
临床怎么用
- 对不适合根治的头颈鳞癌患者,可考虑27Gy/6次姑息IMRT并早期整合姑息治疗以改善生活质量。
- 治疗反应与生活质量相关性弱,临床决策中宜早期评估并关注患者/照护者的生活质量目标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of GOAL27-6 was to evaluate quality of life (QoL) of patients and caregivers, following 27 Gy in 6 fractions palliative IMRT with early integration of palliative care (PC). METHODS: This study included patients with head and neck squamous cell cancer unsuitable for curative treatment, who would accept upfront PC referral. The primary endpoints were QoL assessed with FACT-HN, and treatment-toxicity with CTCAE_v5.0. The secondary endpoints included caregivers' QoL measured with CarGoQoL, treatment-response and survival. Improvement and deterioration in QoL for FACT-HN was pre-defined as ≥ 5% & ≥-10% of the total score respectively, and ≥ 3.65 & ≥-4.13 global-index points respectively for CarGoQoL. RESULTS: The mean FACT-HN scores of 32 eligible patients increased by 5% and 8% at week-12 and 18 (standard deviation SD = 26) post-27 Gy/6f respectively. Seventeen patients (53%) experienced QoL-improvement, 6 (19%) maintained the same, 9 (28%) reported deterioration. There was no ≥ Grade 3 treatment-toxicity. Of the 30 eligible caregivers: 20 (67%) experienced QoL-improvement, 8 (27%) remained the same, 2 (7%) deteriorated. The mean CarGoQoL global-index increased by 6.65(SD = 22) and 8.40(SD = 16) points at week-12 and 18 respectively. Eighteen patients (56%) had complete/partial response, 7 (22%) stable disease and 7 (22%) progressed. The median survival of patients with improved/maintained QoL was 10 months, compared to 4.4 months in patients with deteriorated QoL (p < 0.001). The Spearman correlation between treatment-response and patients' QoL was ρ = 0.23 (p = 0.13). CONCLUSION: Combined 27 Gy/6f IMRT with early PC integration can overall improve patients and caregivers' QoL. With weak correlation between treatment-response and QoL, patients/caregivers' QoL goals may benefit from early exploration.
引用
- Chiu K, Gupta A, Ashraf A, et al. A sinGle-arm phase II study to assess efficacy, tOxicity, and quAlity of life following 27Gy in 6 fractions palliative intensity modulated radiotherapy with early integration of palliative care (GOAL27-6). Radiother Oncol. 2026. PMID: 41936943. doi:10.1016/j.radonc.2026.111524
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。